Skip Navigation Archive: U.S. Department of Health and Human Services U.S. Department of Health and Human Services
Archive: Agency for Healthcare Research Quality www.ahrq.gov
Archival print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

The Role of Stakeholders in the Diabetes Multi-Center Research Consortium (DMCRC) (Text Version)

Slide presentation from the AHRQ 2010 conference.

On September 28, 2010, Joe Selby made this presentation at the 2010 Annual Conference. Select to access the PowerPoint® presentation (1.2 MB).  


Slide 1

The Role of Stakeholders in the Diabetes Multi-Center Research Consortium (DMCRC)

The Role of Stakeholders in the Diabetes Multi-Center Research Consortium (DMCRC)

Joe V. Selby, Director
DMCRC Coordinating Center
Kaiser Permanente Northern CA

Image: The Agency for Healthcare Research and Quality logo. This logo appears in the upper left corner of all subsequent slides.

Slide 2

Diabetes Multi-Center Research Consortium (DMCRC)

Diabetes Multi-Center Research Consortium (DMCRC)

  • Coordinating Center
    • HMO Research Network DEcIDE Center
      • PI Joe Selby, MD
      • Co-PI Patrick O'Connor MD
  • Affiliate Center
    • Johns Hopkins University DEcIDE Center
      • PI Jodi Segal, MD
      • Co-PI Eric Bass, MD
  • AHRQ Project Officers
    • Barbara Bartman, MD MPH
    • Scott Smith, R.Ph., M.S.P.H., Ph.D.

Slide 3

DMCRC-1: Expanded Executive Committee

DMCRC—1
Expanded Executive Committee

  • Also includes:
    • Vanderbilt DEcIDE Center—Marie Griffin MD, PI—Comparative Effectiveness of Oral Agents in Type 2 Diabetes.
    • RTI DEcIDE Center—Suzanne West Ph.D. PI—Comparative Effectiveness of Oral Hypoglycemics on Chronic Kidney Disease and on Time to Initiation of Maintenance Insulin.

Slide 4

Formation and Composition of DMCRC Stakeholders' Committee

Formation and Composition of DMCRC Stakeholders' Committee

  • Formation: June 2009
  • Composition:
    • Expanded DMCRC Executive Committee
    • Government Agencies—AHRQ, NIDDK, CMS, FDA, CDC, VA
    • Clinicians—ACP,AAFP, AADE
    • Patients —ADA, individual patient rep.

Slide 5

Purpose of the DMCRC Stakeholders' Committee

Purpose of the DMCRC Stakeholders' Committee

  • To represent various constituencies and perspectives in a process of nominating and prioritizing topics for AHRQ-funded, empirical CER.
  • To review AHRQ-funded diabetes-related CER and provide input on:
    • Interpretation
    • Dissemination
    • Future Questions

Slide 6

Timeline of DMCRC Stakeholders' Meetings

Timeline of DMCRC Stakeholders' Meetings

Image: Timeline of DMCRC Stakeholders' Meetings.

First Face-to-Face Meeting June 16, 2009: Initial Topic Nominations and Prioritization Focus on Treatment

First Teleconference Feb. 17, 2010: Focus on DM Prevention

Second Face-to-Face Meeting July 1, 2010: Review Ongoing CER Research Topic Re-prioritization for Both Treatment and Prevention

Slide 7

Format of DMCRC Stakeholders' Meetings

Format of DMCRC Stakeholders' Meetings

  • Greetings and Update from AHRQ ~ 30 min
  • Presentation/Discussion of Research ~ 3 hrs
    • Findings from CER Work of Consortium members
    • Review of recent clinical trials findings/implications
  • Nominations for Topics ~ 2 hrs
    • All participants invited to offer nominations
    • Time for Brief Presentations
  • Voting ~ 30 min
    • Assessing preferences of Stakeholders vs. EC
  • Brief Review of Results and Next Steps ~ 30 min

Slide 8

Secrets of the Sauce DMCRC Stakeholders' Committee

Secrets of the Sauce: DMCRC Stakeholders' Committee

  • Meticulous planning with facilitator.
  • Clear goals and game plan.
  • Leave plenty of time for discussion.
  • Facilitator to keep group on track, pull quiet ones out, chair topic nomination segment.
  • Acknowledge relevant work of stakeholders.
  • Demonstrate consequences of prior decisions and prioritization—i.e., funded projects.

Slide 9

Stakeholder Prioritized List of CER Questions on Treatment

Stakeholder Prioritized List of CER Questions on Treatment

  • Compare 2nd line therapies for their long-term effects (e.g., CVD endpoints) – 19 votes.
  • Compare system approaches to coordinated care vs. usual care – 15 votes.
  • Evaluate strategies to remove barriers to self care (including cost barriers) – 15 votes.
  • Compare various providers and sites for providing behavior change support  – 12 votes.
  • Compare strategies for supporting insulin initiation – 9 votes.
  • Compare system-level strategies for supporting adherence to medications – 9 votes.

Slide 10

Stakeholder Prioritized List of CER Questions on Prevention

Stakeholder Prioritized List of CER Questions on Prevention

  • Compare strengthened linkages between primary care and community resources vs. enhancing primary care to address overweight, lifestyle change – 25 votes.
  • What are effective strategies for counseling patients in the primary care setting for weight loss? (Including issues of coverage) – 21 votes.
  • Compare various approaches to GDM prevention and/or prevention of T2 DM in women with GDM.  – 10 votes.
  • Identify effective, affordable ("Chevrolet") programs to support individual behavior change  – 10 votes.

Slide 11

Keeping Stakeholders Engaged

Keeping Stakeholders Engaged

  • Emphasizing the funding by AHRQ of projects that address previously prioritized topics.
  • Presenting and discussing findings from studies they recommended be done.
  • Incorporating their comments and responses into ongoing analyses or taking their suggestions and designing next generation protocols.

Slide 12

Challenges

Challenges

  • Addressing or managing Stakeholder priority topics not squarely in COE purview:
    • Prevention
    • Systems-level approaches
    • Engaging with community
  • Staying on top and keeping Stakeholders on top of all the research that AHRQ is funding.
  • Adding stakeholders from delivery systems, possibly from industry.

Slide 13

Next Steps

Next Steps

Image of the Committee organizational chart.

First tier: Executive Committee—Includes AHRQ, Coordinating, Affiliate Center Leadership

Second Tier: Project Manager

The following committees report to the Project Manager:

  • Data Committee
  • Methods Committee
  • Clinical Committee
  • Stakeholder Committee

Slide 14

Next Steps

Next Steps

Same image as Slide 13 except that there is a two-way arrow between the Clinical Committee and the Stakeholder Committee.

Slide 15

Next Steps

Next Steps

Same image Slide 14 except that there is a two-way arrow between the Methods Committee and the Stakeholder Committee; and a two-way arrow between the Data Committee and the Stakeholder Committee.

Current as of December 2010
Internet Citation: The Role of Stakeholders in the Diabetes Multi-Center Research Consortium (DMCRC) (Text Version). December 2010. Agency for Healthcare Research and Quality, Rockville, MD. http://archive.ahrq.gov/news/events/conference/2010/selby/index.html

 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care